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Dr Ralph J DeBerardinis is a paediatrician, medical gen-
eticist and cancer researcher. He earned MD and PhD
degrees from the University of Pennsylvania before a
residency at the Children’s Hospital of Philadelphia.
He then completed postdoctoral training with Craig B
Thompson at the Penn Cancer Center where he made
novel observations connecting growth factor signaling
to metabolic pathways. These early studies suggested
that alterations in metabolism may be a requirement
for tumor growth.
He now diagnoses and treats children with inborn errors
of metabolism at the University of Texas Southwestern
Medical Center, where he is Director of their metabolic
disease program, as well as continuing his research into
cancer metabolism in the Children’s Medical Center
Research Institute.Altered energy metabolism is now known to be a
widespread feature of cancer cells. Why does a
developing tumour needs to alter its metabolism?
I think it makes most sense to think about that question
in the context of the acquired biological properties that
separate cancer cells from non-malignant cells. Broadly
speaking, cells have to acquire a number of biological
properties in order to become malignant. Those features
are often called the “hallmarks of cancer”, after the land-
mark reviews written by Hanahan and Weinberg. Those
hallmarks include things like sustaining proliferative
signalling, evading growth suppression and resisting
cell death, all of which conspire to lead to pathologic-
ally high levels of cell survival and growth, and ultim-
ately tumorigenesis.Correspondence: Ralph.Deberardinis@UTSouthwestern.edu
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unless otherwise stated.All of those biological properties have to be supported
by metabolic changes in order to meet the demand of
those new activities. That begins to explain why cancer
cells have different metabolic activities. The simplest
conceptually are the ability to evade growth suppression
and to sustain proliferative signalling. Growth metabol-
ism involves the production of energy and the ability to
convert whatever nutrients the cell has available to it
into precursors for macromolecules. In fact, if you
look at the metabolic effects of the signal transduction
pathways that are most often dysregulated in cancer –
particularly the PI3-kinase signaling pathway – a major
role of those pathways is to provide energy and biosyn-
thetic precursors for the cell. That is, activation of the
pathway reprograms metabolism in a way that sustains
growth. These pathways are often constitutively activated
in cancer, so that tumor cells run the metabolic pathways
that allow them to take up nutrients and convert them to
macromolecules at all times.
There are other examples as well. The metabolic ac-
tivities that allow a cell to resist death in the setting
of a stressful microenvironment are also very import-
ant. For example, the ability to maintain energy levels
when nutrients and oxygen become limiting is crucial
to the health of a cancer cell. You can think about
the hypoxia-induced metabolic changes that have
been so well characterised over the years; and also
the ability to maintain reactive oxygen species within
a range that enables growth. The reactive oxygen spe-
cies field is fascinating. These molecules are transient
by-products of normal metabolic processes. They
promote growth if present at modest levels but can
trigger cell death if they become too abundant. BeingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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facilitate cell growth without causing cells to tip over
into death pathways may be a key aspect of tumor
cell metabolism.
So reactive oxygen species have a positive and a
negative effect, depending on their abundance?
Yes, there seems to be a sweet spot. A number of labs
are trying to understand how cells maintain the optimal
balance, and whether upsetting the balance can be used
to drive tumor cells towards death.
One of the emerging themes in cancer metabolism is
the surprising integration that exists between metabolic
activity and signal transduction. We used to think that
metabolism was fairly passive in that it was subject to
the various changes in signal transduction and gene ex-
pression that allow cells to respond to extracellular cues.
But over the last few years we have achieved a much
greater appreciation for the fact that metabolism can
also “push back”; that is, changes in metabolism elicit
their own effects on signaling and gene expression net-
works in very interesting ways. That has been exciting. It
makes some sense if you think about the fact that the
mediators of these signaling processes are largely de-
rived from intermediary metabolism. The methylation
reactions that modify histone proteins and DNA –
they’re derived from amino acid metabolism. There is
very good evidence now that having a primary meta-
bolic disturbance affects other dimensions of systems
biology that we thought largely existed to regulate
metabolism, not the reverse.
So when you say a “metabolic disturbance” – does this
link with diet, with obesity, with diabetes? Do they feed
into these pathways?
Probably so. One simple example is that the acetylation
state of proteins – particularly metabolic enzymes in the
mitochondria – fluctuates with the feed/fast state in the
liver. That may also apply to tumors characterized by very
high rates of nutrient uptake. Whether these systems be-
come deranged in the setting of more chronic conditions
like obesity and diabetes is unknown, but is obviously an
important area of research because of the fact that those
conditions increase the risk of certain forms of cancer.
Probably the most exciting thing that’s emerged from
cancer metabolism research is the fact that there are
mutations in metabolic enzymes that independently in-
fluence cancer risk. Mutations in components of the
succinate dehydrogenase complex in paraganglioma and
pheochromocytoma; mutations in fumarate hydratase
(FH) in renal cell carcinoma; and mutations in isocitrate
dehydrogenase-1 and −2 (IDH1 and IDH2) that occur in
a significant fraction of gliomas, acute myeloid leuke-
mias and other forms of cancer. All of these mutationscause major perturbations in metabolism at the cellular
level. The ripple effects that emanate from those meta-
bolic perturbations impinge on signal transduction and
gene expression programs in ways that appear to pro-
mote malignancy.
The altered metabolism of cancer is to allow the
proliferation of cells by generating more energy, and
extra building blocks. The research that you and others
have done has shown a high requirement for the amino
acid glutamine in cancer. Is this a particularly important
nutrient for cancer?
Yes, it seems to be, at least in some forms of cancer. The
way I think about it is to ask: which features would make
a nutrient most useful to a tumour cell? It should be
abundant and it should be versatile. It should be able to
supply a number of metabolic needs for the cell. Glutam-
ine certainly fulfils those two criteria; it’s the most abun-
dant circulating amino acid in humans – and it’s also
versatile because of its position in the metabolic network.
It can feed a very large number of pathways that promote
cell survival and growth. Glutamine is a major shuttle that
traffics both carbon and nitrogen between organs, mean-
ing that it can provide precursors for basically all of the
major macromolecular classes. When cells divide, they
need to make proteins, nucleic acids and lipids. Glutamine
feeds all of those pathways in various interesting ways. It’s
also a precursor to synthesize the antioxidant glutathione
and to produce NADPH, which keeps glutathione in a re-
duced state. Both of these are required to maintain pro-
ductive reactive oxygen species levels.
Glutamine also feeds a number of other pathways that
we don’t conventionally consider to be metabolic. In many
cells, glutamine is the major precursor of alpha-
ketoglutarate. In addition to being an intermediate in the
Krebs cycle, alpha-ketoglutarate is a substrate for a large
family of dioxygenase enzymes that modify proteins and
DNA. This plugs glutamine into a much broader bio-
logical network than you could predict just by studying
the metabolic charts. Importantly though, there are also
cancer cells and tumors that quite clearly don’t consume
high amounts of glutamine. We don’t entirely understand
why that’s the case, except to say that in the situations
where we’ve looked, the cells have found alternatives to
supply those same metabolic pathways with different nu-
trients, particularly glucose or other amino acids.
So it’s the versatility of glutamine – it’s a food source that
can go into these multiple pathways, that make it an
ideal nutrient for cancer.
Yes. If you imagine a cell that’s trying to grow as rapidly
as possible, that cell needs easy access to abundant
nutrients that can feed a large number of pathways
simultaneously. Glutamine is great for that.
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you diagnose and treat children with inborn errors of
metabolism. I wonder if you can tell us about those
diseases and what we can learn from them?
I really think we can learn a lot from these diseases. In-
born errors of metabolism are genetic diseases, usually
recessively inherited. They involve severe mutations in
metabolic enzymes and nutrient transporters. There are
many, many of these diseases involving basically every
metabolic pathway. Individually, these are rare diseases,
but altogether there are hundreds of them. If you add
them together, they become one of the largest categories
of human genetic diseases and account for a substantial
fraction of inpatient hospitalization in pediatric hospi-
tals. They provide us with unique insights into the
importance of specific metabolic activities, because indi-
viduals with these diseases are analogous to knockout
models for so many different components of the meta-
bolic network.
So what we can learn from them about cancer? First,
they provide an opportunity to understand the overlap
between cancer and metabolic dysfunction. This is par-
ticularly true of the relatively small number of inborn er-
rors of metabolism that are associated with an increased
risk of cancer. One obvious example is a disease called
(L)-2-hydroxyglutaric aciduria. This is a very rare condi-
tion where patients lack the enzyme that converts one of
the enantiomers of a metabolite called 2-hydroxyglutaric
acid into the Krebs cycle intermediate alpha-ketoglutarate.
This metabolite, 2-hydroxyglutaric acid, or 2-HG, has
generated a tremendous amount of interest recently be-
cause it is also produced in large quantities by the mutant
forms of IDH1 and IDH2 that occur in gliomas, acute
myeloid leukaemias and other cancers. But there are these
very rare patients that have accumulations of 2-HG for a
completely different reason – they lack the downstream
enzyme that allows 2-HG to be converted into alpha-
ketoglutarate. Amazingly enough, those patients develop
brain tumors. In fact that condition is essentially the only
inborn error of metabolism that’s been associated with
central nervous system malignancies.
What’s the rate of brain cancer in these patients?
It’s hard to say because the disease is so rare, but it
seems to be higher than 10%.
It’s very interesting that the form of 2-HG that accu-
mulates in the children with brain malignancies because
of this metabolic disease is the (L)-enantiomer. But the
opposite enantiomer – the (R)-enantiomer, accumulates
in adult cancer patients with somatically acquired muta-
tions in IDH1 and IDH2. Given the right context, it
seems those two structurally related but different metab-
olites converge on a phenotype that gives an increased
risk of malignancy, both in a child with an inborn errorof metabolism and an adult with IDH1 or IDH2 muta-
tions confined to the tumor. That will likely turn out to
be an important clue about the pathogenesis of both
diseases.
Conversely, we’ve learned so much about metabolic
regulation now by studying cancer that it would be useful
to try to use that information to better understand inborn
errors. It’s quite possible that some of the agents that have
been developed to try to manipulate metabolism in cancer
will find a clinical home in patients with inborn errors.
Certainly, the technologies that we’ve developed to moni-
tor metabolic activity in tumors should also be useful in
pediatric metabolic diseases. I’m excited about that.
Do we see the same mutations in children with inborn
errors of metabolism as we see drive altered metabolism
in a developing tumor in a cancer patient?
In some cases, yes. In other cases, the metabolic distur-
bances are similar even if the mutations causing them
are different. For example, there’s an inborn error of me-
tabolism called glycogen storage disease type 1, which
causes excessive accumulation of glycogen in the liver
and kidney. The plasma of these patients contains high
levels of lactate, lipids, and nucleotide metabolites, all
of which you also see in cancer cells that exhibit the
Warburg effect. Those patients have a long term risk
of developing cancer in the liver, so it would be very
interesting to understand what promotes malignancy
in the setting of this metabolic disturbance.
I think the last thing to mention about patients with
inborn errors in metabolism is that, as I said, these pa-
tients show us the consequences of severe loss of function
of specific metabolic activities. Many of the enzymes that
have been considered as targets for metabolic therapy in
cancer – for example lactate dehydrogenase (LDH)-A –
are mutated in inborn errors of metabolism. There are in-
dividuals with severe, whole-body LDH-A deficiency. So
the question inevitably comes up, as drug companies es-
tablish programs in cancer metabolism: what toxicities do
we need to worry about if we try to block LDH-A? One
can study patients with the relevant disease and at least
get some idea of which organ systems might be affected
by the therapy.
You’ve mentioned some potential therapeutics and I
wonder whether these recent discoveries on the basic
biology of cancer metabolism – of which there are now
many –– have they yet changed the way we diagnose
and treat patients with cancer?
Yes, they have. There’s actually a long track record of suc-
cess for metabolic therapy in cancer. One of the best ex-
amples is L-Asparaginase. L-Asparaginase is an enzyme
that degrades the amino acid asparagine. It’s used to treat
leukemias, particularly acute lymphoblastic leukemia in
DeBerardinis Cancer & Metabolism 2014, 2:5 Page 4 of 4
http://www.cancerandmetabolism.com/content/2/1/5children. It’s been around for decades and it is effective
because very rapidly growing cells require more aspara-
gine to support protein synthesis than they can synthesize
themselves.
L-Asparaginase depletes asparagine in the plasma,
starving the cancer cells. So this is really a form of meta-
bolic therapy, and it is a big part of the reason why the
cure rate in pediatric leukemias is now so high.
But more recently, I think the best example is what’s
happened with the discovery of IDH1 and IDH2 muta-
tions. These mutations were identified just about six
years ago in glioma. In 2009, it was demonstrated by the
team at Agios that mutations in IDH1 are associated
with high levels of 2-HG in the tumor. Following this
discovery, it’s become possible at several hospitals to
non-invasively monitor the levels of 2-HG in brain tu-
mors using MRI. This means that no biopsy is needed to
detect high levels of the metabolite. The 2-HG levels,
measured using MRI, correlate 100% with whether the
tumor has a mutation in IDH1 or IDH2, again without
the need to get any tissue.
So the altered metabolism in the cancer allows you to see
it using MRI?
That’s right. 2-HG is vanishingly scarce in most tissues.
In tumours that have these mutations in IDH1 or IDH2,
it accumulates to millimolar levels, high enough to de-
tect by a technique called MR spectroscopy, similar to
MRI. So it becomes possible to tell the patient on the
day of the MRI scan whether or not there is an IDH1 or
IDH2 mutation in the tumour.
That’s important for two reasons: first – because the
tumor is more likely to be lower grade, that is, less ag-
gressive, if there is a mutation in IDH1 or IDH2; and
second – drugs have now been developed specifically to
inhibit the mutant isoforms of IDH1 and IDH2 that
occur in these tumours. So you can imagine a situation
where the patient has the imaging test to detect 2-HG,
then information from the scan is used to determine
whether or not the patient should receive the drug. So
in just six years of research, we went from identifying
mutations in IDH1 and IDH2, to a sophisticated under-
standing of the biological consequences of those muta-
tions, and now we have new clinical imaging strategies
and new therapeutic strategies – all built around the al-
tered metabolism. It’s very exciting, both from the per-
spective of new biology and because of the possibility of
a new therapy for a terrible disease.
Are there other new diagnostics and new treatments that
we’ll see over the next few years based on discoveries in
cancer metabolism happening today?
I think the pace is accelerating. In the imaging field, an-
other exciting advance is a technique called carbon-13hyperpolarisation. This is a way to image not metabolites
per se but actual metabolic activity, in real time, using
another MRI-related approach. This technique massively
increases the visibility of labelled carbons on metabolite
tracers. For example, a hyperpolarised form of pyruvate
can be injected and imaged as it is converted into lactate
by the tumor, giving a real-time view of the tail end of
the glycolytic pathway. This approach has been used for
several years in mouse models of cancer and just last
year was used successfully in humans for the first time
by a group at UCSF studying prostate cancer.
Can you explain the importance of being able to measure
and visualise the metabolism in the tumour?
Well, using the example of prostate cancer: these tumors
are very difficult to image using other techniques. Con-
ventional MRI is usually not sufficient and FDG PET,
which is the most widely used form of metabolic im-
aging in cancer, is also inadequate in prostate tumors. So
the hope is that hyperpolarised MRI techniques will
allow oncologists and radiologists to better differentiate
malignant prostate tissue from benign tissue. But there
may be many other applications as well. There is a great
deal of evidence that oncogenes regulate the rate of
metabolic pathways, not just the abundance of metabo-
lites. So the rate of the pathway serves as a biomarker
for the effect of the oncogene, or conversely a sup-
pressed rate may indicate that the tumor is being treated
successfully. The hope is that hyperpolarisation and
other new metabolic imaging techniques will substan-
tially broaden the view of metabolism that can be ob-
tained from live tumors. That would have great impact
both on the types of research questions that can be
asked in human subjects, and in the way we diagnose
and monitor cancer in our patients.
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